請由右方點選想進一步了解的主題
了解費森尤斯卡比到2026年有甚麼計畫
費森尤斯卡比的過去以及現在發展
企業社會責任
請由右方點選想進一步了解的產品類別
生物相似藥
醫療儀器
靜脈注射藥品
癌症用藥
腎臟營養
週邊靜脈營養
腸道營養
在找工作嗎?歡迎加入我們
For us, integrity means doing the right thing – by fostering a culture of accountability and transparency within our company and with our partners.
在此閱讀費森尤斯卡比的相關新聞、最新消息或動人故事分享。
Q3/2025: Strong organic revenue and excellent EPS growth; EBIT growth guidance raised
Explore how biosimilars drive smarter healthcare investment and global access with Fresenius Kabi’s support for Biosimilars Week 2025.
Recognized by Vizient for supply assurance and strategic collaboration, Fresenius Kabi earns two major awards.
Dr. Hannah Wozniak receives €250,000 JUMPstart Clinical Nutrition research award for a personalized nutrition and early mobilization trial in ventilated patients.
Fresenius continues to reduce complexity and increase efficiency in its global network. In line with #FutureFresenius, the company announces the divestment of Fresenius Kabi’s Calea homecare business in Canada.
Fresenius is collaborating with other companies and academic institutions with the goals of accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe.
Q2/2025: Ongoing strong revenue and EPS growth, guidance for organic revenue growth raised
Fresenius Kabi will exclusively commercialize Polpharma Biologics’ vedolizumab biosimilar candidate PB016 globally (except in the Middle East and North Africa).
Fresenius announced that the European Commission has granted approval for their denosumab biosimilars Conexxence®* and Bomyntra®* in Europe.
Dr. Wan Daud from Malaysia receives €100,000 research support through the JUMPstart Renal Nutrition Therapy Program to conduct her CKD nutrition study.
Recognized for service and innovation, Fresenius Kabi earns its 5th Premier award. Discover how we help hospitals improve care and reduce costs.
NutriKabina by Fresenius Kabi is a telehealth innovation that enables fast, accessible nutrition screening for oncology patients in hospitals across Argentina.
Fresenius Kabi advances responsible antibiotic manufacturing with AMR certification at its Portugal site: protecting public health for future generations.
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®.
Fresenius Kabi’s fifth and sixth biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) are now available in the U.S. for all approved indications for their respective reference products, Prolia® (denosumab) and Xgeva® (denosumab).
Discover how Fresenius Kabi is expanding global R&D centers for Nutrition. Explore the new locations driving excellence.
Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization of its biosimilar candidates to Prolia® (denosumab) and Xgeva® (denosumab).
Q1/2025: Strong top line and excellent EPS growth, outlook confirmed
Discover best practices in perioperative nutrition from leading surgical experts. Four podcast episodes on surgery and nutrition management.
Lizl Veldsman from South Africa wins the award for her study on preventing muscle loss in ICU patients, supported by Fresenius Kabi's research grant.
Fresenius Kabi optimizes production network: Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS.
Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the FDA.
We were honored to welcome over 100 healthcare professionals from 33 countries to our headquarters for the FRANC2024 Oncology – the Fresenius Kabi Advanced Nutrition Conference.
Learn more about chronic kidney disease and how health care professionals play a crucial role in early detection and patient education.
Fresenius Kabi’s ustekinumab biosimilar Otulfi® (ustekinumab-aauz), developed by Formycon AG, is now available in the United States and European Union.
FY/24: Upgraded outlook achieved, consistent financial performance with profitable growth.
With this mentoring program, Fresenius Kabi supports early-career clinicians and researchers through education, networking, and funding opportunities.
To further advance research and medical education in the field of intensive care medicine, Fresenius Kabi continues its collaboration with ESICM in 2025.
Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. FDA has granted 510(k) clearance to its Adaptive Nomogram.
Fresenius Kabi is a Top Employer in 2025, with twelve countries receiving certification from the Top Employers Institute.
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm (SCD).
Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States.
Search
搜尋
本產品係供靜脈(IV)輸注藥物之輸液幫浦,僅供專業人員於醫院內使用。
醫療器材
衛部醫器輸字第030895號
如要查看仿單詳細內容,請點下方按鈕
適用需要進行靜脈注射治療之病患。僅醫院的專業人員方可使用本空針微量輸液幫浦。
衛部醫器輸字第030902號
可整合多台空針微量輸液幫浦與輸液幫浦提供更有效的病房空間管理,適用於任何需要輸注治療之病患
衛部醫器輸字第032557號,請點擊下列按鈕前往網站查詢。
本產品係供靜脈(IV)輸注藥物之專用輸液套,僅能裝置於艾捷莉輸液幫浦,需由專業人員於醫院內使用
醫療器材之專用耗材
衛部醫器輸字第028688號 / 衛部醫器輸字第034310號
本產品為搭配專用餵食套組使用之灌食機,專用於腸道營養及水份餵食
衛部醫器輸字第031586號,請點擊下列按鈕前往網站查詢。
本產品搭配愛美克斯分離套組使用,用於收集血小板、
衛署醫器輸字第022043號,請點擊下列按鈕前往網站查詢。
移除紅血球濃縮液中之白血球
衛部醫器輸字第032423號,請點擊下列按鈕前往網站查詢。
去除血小板濃縮液中之白血球
衛署醫器輸字第011642號,請點擊下列按鈕前往網站查詢。
B.9750加熱密封器材是醫用器材,用於將含血液及血液產品的塑膠袋加熱密封
衛部醫器輸壹字第013516號,請點擊下列按鈕前往網站查詢。
提供三種全自動程式,針對沖洗,血液的傳輸及血漿分離術。依連續離心之原理,將自動處理並且進行自體回 收給予病患在手術中以及手術後因手術或外傷所流失之血液。將病患血液收集至已滅菌之儲血槽,經連續沖洗 程式所分離之處理過紅血球,再輸送至病患。在此過程,收集的血液中之血漿、未生成紅血球細胞成份、活化 的凝固因子、纖維素溶解物、細胞的碎片以及抗凝劑將被分離出。
衛部醫器輸第036309號,請點擊下列按鈕前往網站查詢。
免針輸注閥用於靜脈注射和血液輸液,並具有中性液體位移功能。對象是靜脈注射治療的患者,使用取決於患者的情況,由合格的醫事人員負責。
醫療器材(單次使用)
衛部醫器輸字第 036969 號
Conox 適用於進行全身麻醉或鎮靜的患者使用。
Conox 適用於受過麻醉訓練的醫事人員使用。
Conox 適用於醫院、醫療機構和救護車使用。
Conox 透過患者的腦電圖(EEG)資料演算,提供初級和二級指標:
初級指標:
qCON:0-99 的無量綱(dimensionless)尺規範圍,做為評估患者意識狀態的指引。
二級指標:
qNOX:0-99 的無量綱(dimensionless)尺規範圍,做為評估患者對傷害性刺激做出反應的可能性。
衛部醫器輸字第037189號
C.A.T.S.和 CATSmart 自體血液回收系統及其單次使用產品是自體血液回收裝置,用於處理術中和術後收集的自體回收血液,以獲得洗滌過的濃縮紅血球用於再輸注。此外,它還用於手術前後期將血液分離成濃縮紅血球、血漿和富含血小板的血漿。
9305103, 9308551, 9308552, 9308553
衛部醫器輸字第037213號
衛部醫器輸第033948號
本產品主要用於Patient Control Analgesia PCA 治療,用於在病患或臨床醫師的控制下注射止痛藥。
衛部醫器輸字第033902號
用於輸液幫浦的靜脈給藥裝置。對象是靜脈注射治療的患者,由醫事人員依患者的情況使用。
衛部醫器輸字第037293號
當無法進行正常口服營養時,本產品用於腸道管灌餵食。
本產品用於將營養品或飲食從營養袋進入到管內進行腸道管灌餵食。
衛部醫器輸字第032248號
當無法進行正常以口進食時,用於預防和治療營養不良的腸內營養給藥。
本產品用於將營養袋中的營養品或飲食藉由腸內餵食管餵食。
衛部醫器輸字第031948號
請參閱仿單說明
衛署醫器輸字第017380號
型 號:9305101、9348411、9308471、9308481、9308491、9308501
衛署醫器輸字第017511號
型 號:9308401、9308431
衛署醫器輸字第017522號
型 號:9305141
衛部醫器陸輸字第001660號
型 號:
衛部醫器輸字第037790號